Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OTLK vs CSBR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OTLK Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

OTLK Overall Winner 6-Pillar Tally: OTLK 3 – 3 CSBR Matrix Metrics: OTLK 8 – 2 CSBR

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CSBR carries 42.9/100 (HOLD) at $4.71 (47.0x Forward P/E, -1.5% operating margin).

  • Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CSBR 42.9/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CSBR leads top-line expansion (+8.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OTLK vs CSBR
OTLK NASDAQ Head-to-Head Winner
Outlook Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.40
-4.04% 1D
Market Cap $107.1M
TTM Revenue N/A
Forward P/E 2.9x
Beta / 30D Vol 1.47β · 79% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 71.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.5%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.48 · SMA50: $0.56
CSBR NASDAQ
Champions Oncology, Inc.
Biological Products, (No Disgnostic Substances)
$4.71
+1.18% 1D
Market Cap $64.7M
TTM Revenue $61M
Forward P/E 47.0x
Beta / 30D Vol 0.36β · 24% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 46.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.0%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $4.79 · SMA50: $4.90

6-Pillar Scorecard Institutional Category Breakdown (OTLK 3 – 3 CSBR)

Columns: Metric · OTLK · CSBR
1. Valuation Multiples OTLK
Forward P/E 2.9x 47.0x
Trailing P/E 2.9x 22.9x
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale CSBR
Revenue Growth (YoY) -99.4% +8.8%
Earnings Growth (YoY) +0.0% -61.1%
TTM Revenue (USD) N/A $61M
Market Cap $107.1M $64.7M
3. Profitability & Quality OTLK
Gross Margin N/A 49.8%
Operating Margin 4781.8% -1.5%
Net Profit Margin 0.0% -1.9%
Return on Equity (ROE) -3.6% -28.4%
4. Balance Sheet & Cash Flow CSBR
Cash Generation (TTM) -$56M $402,000 EBITDA
Cash Flow Margin N/A 0.7% EBITDA Mgn
Net Cash / Leverage $7.2M Net Debt $0.28 Book/Sh · -28.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OTLK
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 181.3% (55th %ile) N/A (N/A)
Put/Call OI Skew 0.26x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CSBR
OpEx & R&D Intensity N/A 51.3% of Rev ($31M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OTLK (8) vs CSBR (2)
Institutional Metric OTLK CSBR Criterion Row Edge
Market Capitalization
Scale
$107.1M $64.7M Larger Scale OTLK
Trailing P/E Ratio
Valuation
2.9x 22.9x Lower Multiple OTLK
Forward P/E Ratio
Valuation
2.9x 47.0x Lower Multiple OTLK
Revenue Growth (YoY)
Growth
-99.4% +8.8% Higher Growth CSBR
Operating Margin (TTM)
Profitability
4781.8% -1.5% Higher Margin OTLK
Net Profit Margin
Profitability
0.0% -1.9% Higher Margin OTLK
Return on Equity (ROE)
Capital Efficiency
-3.6% -28.4% Higher ROE OTLK
52-Week Range Position
Momentum
10% ($0–$3) 5% ($5–$8) Stronger Trend OTLK
Beta / 30D Volatility
Risk Regime
1.47β · 79% Vol 0.36β · 24% Vol Lower Realized Risk CSBR
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 42.9 / 100 (HOLD) Higher Composite OTLK
Trailing 12M Revenue (USD)
Operating Scale
N/A $61M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 49.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$56M ($7.2M Net Debt) $402,000 EBITDA ($0.28 Book/Sh · -28.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CSBR +15.63 pp
OTLK: -17.4% · CSBR: -1.77%
3M Horizon CSBR +32.1 pp
OTLK: -38.56% · CSBR: -6.46%
6M Horizon OTLK +105.17 pp
OTLK: +81.06% · CSBR: -24.11%
1Y Horizon CSBR +40.09 pp
OTLK: -71.9% · CSBR: -31.81%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OTLK vs CSBR. Trailing 12-month operating profitability (OTLK 4781.8% vs CSBR -1.5%) and valuation multiples (OTLK 2.9x vs CSBR 47.0x Forward P/E) are benchmarked directly in Pillar 4 below.

OTLK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin4781.8%
ROE / Fwd P/E-3.6% · 2.9x
CSBR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$61M
Gross Margin49.8%
Op. Margin-1.5%
ROE / Fwd P/E-28.4% · 47.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OTLK BREAKDOWN
103d in phase · OBV NEUTRAL
Current IV 181.3%
IV Percentile 55th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact OTLK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CSBR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CSBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OTLK Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CSBR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $64.7M market capitalization and -1.5% operating margin.
OpEx & R&D Reinvestment 51.3% of Rev ($31M)
90D Engineering Disclosures 0 Published

Investor FAQ OTLK vs CSBR Key Questions & Quantitative Answers

As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). OTLK carries a Unified Composite Score of 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin), whereas CSBR carries 42.9/100 (HOLD) at $4.71 (47.0x Forward P/E, -1.5% operating margin). Growth vs. Quality Trade-Off: OTLK earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CSBR 42.9/100 HOLD) and 1.47β · 79% Vol risk profile, whereas CSBR leads top-line expansion (+8.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OTLK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CSBR leads the Growth & Scale pillar: OTLK posts -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin), compared with CSBR at +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin). On trailing 12-month operating scale, OTLK generates N/A in USD-normalized revenue versus $61M for CSBR. In operating R&D and SG&A reinvestment, OTLK deploys N/A (0 90-day corporate R&D disclosures) versus 51.3% of Rev ($31M) (0 disclosures) for CSBR.

OTLK screens cheaper on headline valuation multiples. OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CSBR trades at 47.0x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (0.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OTLK (-3.6% ROE) versus CSBR (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk). By comparison, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.